SiSaf Ltd Announces US$13.2 Million Series B Financing
Non-invasive ocular siRNA delivery induces effective gene silencing in corneal epithelium
SiSaf announces licencing agreement to develop gene therapy for rare bone disease
SiSaf Makes Its Bio-Courier® Technology Available for COVID-19 Vaccine Research
Next Page »
Find out more.
Okay, thank you